HANSHOW
28.2.2024 10:59:29 CET | Business Wire | Press release
Hanshow, a leader in retail technology innovation, today unveiled a series of Green Store Solutions, designed to accelerate the retail industry towards a sustainable future. Complementing this new product, Hanshow has also released a comprehensive Green Digitalization Report alongside tech partners Microsoft, Intel, and E Ink.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240223583112/en/
Hanshow at EuroCIS 2024 (Photo: Business Wire)
The Polaris Pro Electronic Shelf Labels (ESL) series stands out with its high screen-to-body ratio, multi-color display capabilities, and user-replaceable battery system designed for longevity, embodying Hanshow's commitment to sustainability. This advanced ESL solution is set to reduce paper waste, improve pricing accuracy, and enhance the overall aesthetic of modern retail environments.
Building on the innovative leadership of the Polaris Pro, Hanshow's Green Store Solutions extend beyond ESLs to include dynamic in-store marketing and AI-driven solutions. These innovations optimize store performance through targeted promotions, precise inventory management, and real-time data insights, facilitating smarter, greener operations.
To push the boundaries of what is possible in retail further, Hanshow integrates GenAI technology into its digital retail Solutions, enhancing operational efficiency and customer experiences. This adoption of GenAI simplifies complex processes and decision-making, making retail operations more efficient and intuitive. GenAI serves as an assistant to both store associates and customers, enabling easier navigation, personalized shopping experiences, and enhanced staff productivity.
Hanshow’s authoritative Green Digitalization Report, highlighting the dual benefits of digitalization and sustainability. The report, produced in cooperation with Microsoft, Intel, and E Ink, offers a deep dive into how retailers can use green digitalization as a double engine for growth, marrying eco-efficiency with cutting-edge innovation.
"Hanshow is proud to be at the forefront of the movement towards a greener, more digital future for retail," said Liangyan Li, SVP and Head of Global Sales at Hanshow. "With the introduction of the Polaris Pro series and our comprehensive Green Store Solutions, including our pioneering work on GenAI, we are paving the way for retailers to operate sustainably without compromising on customer satisfaction or operational excellence."
To further promote the many exciting ways in tech technology is laying a stronger foundation for sustainability in the retail industry, Hanshow’s Green Digitalization Report outlines actionable strategies to integrate sustainability into core business operations through innovative technologies. The report was released jointly with important contributions from industry partners such as Microsoft, Intel, and E Ink, and emphasizes myriad ways in which new technological advancements in AI, IOT, and data-driven decision-making will optimize management, reduce resource waste and store costs, improve associates’ work productivity and job satisfaction, and more accurately track and adjust customer experiences both in-store and online, all while helping retailers to meet sustainability targets.
Retailers eager to explore the Polaris Pro series, the suite of Green Store Solutions, and the findings of the Green Digitalization Report are invited to connect with Hanshow's team. Demonstrations and consultations are available to showcase how these initiatives can be seamlessly incorporated into existing retail frameworks.
About Hanshow
Hanshow is one of the global leaders in the development and manufacturing of electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores across more than 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240223583112/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom